MiMedx Q2 net sales $81.3M (+21.5% YoY); raises FY2023 growth guidance to mid-to-high teens

MIMEDX GROUP, INC.

2023-Q2 EPS reported -$0.06 revenue$152,933,000

Net sales $81.3M (+21.5% YoY); net income $1.2M; Adj. EBITDA $14.1M (17.4% of sales).
Raises full-year 2023 net sales growth guidance to mid-to-high teens.
Appoints Doug Rice as CFO, rounding out executive team.
Reports favorable appellate ruling affirming dismissal of securities class action.
Announced strategic realignment focusing on Wound & Surgical businesses to improve profitability.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MIMEDX GROUP, INC. reported second quarter ended June 30, 2023 results: revenue $81.3 million, net income $1.2 million. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $81.3 million
Net income: $1.2 million
Guidance: raised
Result: reported results

Exact text from the filing

report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 MIMEDX Announces Second Quarter 2023 Operating and Financial Results Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer

View on SEC.gov

Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-200535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.